Skip to content
Popular Searches
  • # Cancer
  • # FDA
  • # Alzheimer's
  • # Johnson&Johnson
  • # Hoffmann-La Roche
  • # FDA Approval
  • linkedin
  • facebook
  • instagram
  • twitter
  • youtube
Home BiotechReality – Covering Industry, Business, and Academia

Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.

  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
Trending

Trending

Reprogramming of T cells to fight against ageing – Research

31 January 2024

Intriguing New Class of Antimalarial Drugs Discovered

21 February 2025

Elecsys PRO-C3: Roche’s Precision Test for Liver Fibrosis

6 May 2025

UPMC and Penn State Scientists Unveil Next-Generation mRNA Vaccine Platform to Tackle Rapidly Mutating Viruses

5 June 2025

Diagnosis of bipolar disorder is very simple using a blood test to identify biomarkers; A study at the University of Cambridge

27 October 2023

Combination of chemotherapy and dual-targeted treatments Phase III Breakwater Clinical trials supported for BRAF-mutated metastatic colorectal cancer FDA approval

26 January 2025

Nitrogen Fixation – Overview

4 September 2023

Glycolysis – Pathway and Process Overview

22 October 2024

Mitochondrial protein synthesis disruption in Alzheimer’s disease can be caused by RNA modification

7 May 2024

Based on Results From the Phase 3 BRUIN CLL-321 trial, Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union

1 March 2025

Eyestem Announces Positive Safety Results in Phase 1 Trial of RPE Cell Therapy

18 June 2025

Researchers at University of Oxford developed 3D printing for repairing brain injuries

6 October 2023

Abbott

Abbott’s Tendyneâ„¢ Device Receives FDA Approval for Minimally Invasive Mitral Valve Replacement
Healthcare & Pharmaceuticals Medical Devices News Regulatory Approval

Abbott’s Tendyneâ„¢ Device Receives FDA Approval for Minimally Invasive Mitral Valve Replacement

Athulya B S 28 May 2025

Abbott’s Tendyneâ„¢ device has secured FDA approval, revolutionizing mitral valve replacement. This minimally invasive system offers a crucial alternative for high-risk patients with severe mitral annular calcification, eliminating the need for open-heart surgery.

Abbott’s FreeStyle Libre® Technology Linked to Significant Reduction in Heart-Related Hospitalizations for Diabetes Patients
Clinical Trials Diabetes Medical Devices News

Abbott’s FreeStyle Libre® Technology Linked to Significant Reduction in Heart-Related Hospitalizations for Diabetes Patients

Ajmal Aseem 16 May 2025

In addition, the research showed an 80% reduction in the hospitalization risk of cardiovascular disease in individuals with Type 1 diabetes who did not have a previous history of such illnesses.

Abbott Released New Clinical Trial Data Shows Long-Term Benefits of Voltâ„¢ PFA System
Clinical Trials Healthcare & Pharmaceuticals News

Abbott Released New Clinical Trial Data Shows Long-Term Benefits of Voltâ„¢ PFA System

Athulya B S 27 April 2025

In contrast to conventional cardiac ablation techniques, PFA therapy targets specific cardiac tissue regions with high-energy electrical pulses that result in irregular heartbeats.

Abbott’s Voltâ„¢ Pulsed Field Ablation System Receives CE Mark to Treat Patients with Abnormal Heart Rhythms
Business Healthcare & Pharmaceuticals News

Abbott’s Voltâ„¢ Pulsed Field Ablation System Receives CE Mark to Treat Patients with Abnormal Heart Rhythms

Editor's Desk 31 March 2025

AFib affects around 8 million Europeans over the age of 65, and this figure is anticipated to grow over the next 30 years.

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • Cell Biology
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Life Sciences
  • Machine Learning
  • Medical Devices
  • Mental Health
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs
Market Analysis
Publish on BiotechReality

  • Amgen Hiring a Business Intelligence (BI) Architect in Hyderabad, India
  • Cytiva Hiring a Quality Control Technician in Cardiff, United Kingdom
  • PhD Position in Dialysis Therapy – University of Twente, Netherlands
  • Eli Lilly and Company Hiring a Analytical Technical Steward-Peptides in Hyderabad, India – June, 2025
  • ICON Hiring a Clinical Data Programming Lead in Chennai, India
SciRealityPress BiotechReality

A SciRealityPress Associate

DMCA.com Protection Status

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2025
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinuePrivacy policy